Stoke Therapeutics, Inc.
STOKNasdaq
$29.05
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +144.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.8B
Enterprise Value
$1.5B
P/E
—
P/S
57.1
P/B
4.6
EV/EBITDA
—
PEG
—
FCF Yield
-8.1%
Dividend Yield
—
Revenue (TTM)
$32.1M
Net Income (TTM)
-$169.8M
Free Cash Flow (TTM)
-$147.7M
Gross Margin
—
Operating Margin
-577.5%
Net Margin
-529.2%
ROE
-43.0%
ROIC
-285.1%
Debt / Equity
—
Net Cash
$343.5M
Return 1Y
+135.2%
Company profile
Stoke Therapeutics, Inc. develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy.
- CEO
- Edward M. Kaye
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Massachusetts
- Website
- stoketherapeutics.com
Management & directors
- Ticho BarryCHIEF MEDICAL OFFICER
- Allan JonathanGENERAL COUNSEL & CORP SEC
- Hoitt JasonChief Patient Officer
- Leggett ThomasChief Financial Officer
- Tzianabos ArthurInterim Executive Chair
Roles derived from SEC Form 4 filings.
Earnings
STOK Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$6.2M↓ -96.1%
Diluted EPS-$0.79↓ -141.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $12.4M | $8.8M | $36.6M | $184.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$53.0M | -$86.1M | -$104.4M | -$114.8M | -$101.4M | -$20.6M |
| Net income | -$52.2M | -$85.8M | -$101.1M | -$104.7M | -$89.0M | -$6.9M |
| Diluted EPS | — | -$2.34 | -$2.60 | -$2.38 | -$1.65 | -$0.12 |
| Operating cash flow | -$42.2M | -$66.9M | -$31.9M | -$81.1M | -$86.9M | $45.6M |
| Free cash flow | -$43.3M | -$68.1M | -$35.8M | -$82.7M | -$87.1M | $44.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | -841.2% | -1307.2% | -277.3% | -11.2% |
| Net margin | — | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8M | $4.9M | $22.6M | $158.6M | $13.8M | $10.6M | $1.4M | $6.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$29.3M | -$30.0M | -$13.7M | $111.2M | -$27.3M | -$43.1M | -$61.4M | -$53.4M |
| Net income | -$25.7M | -$26.4M | -$10.5M | $112.9M | -$23.5M | -$38.3M | -$57.9M | -$50.0M |
| Diluted EPS | -$0.46 | -$0.47 | -$0.15 | $1.90 | -$0.40 | -$0.65 | -$0.97 | -$0.79 |
| Operating cash flow | -$17.5M | -$21.6M | -$23.2M | $131.8M | -$25.4M | -$30.4M | -$30.5M | -$60.6M |
| Free cash flow | -$17.5M | -$21.7M | -$23.2M | $131.7M | -$25.6M | -$30.5M | -$30.7M | -$60.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -607.4% | -613.1% | -60.4% | 70.2% | -197.6% | -405.3% | -4382.2% | -857.6% |
| Net margin | -531.9% | -540.0% | -46.4% | 71.2% | -170.0% | -360.7% | -4132.2% | -802.7% |
Company news
Jul 16, 2026
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 6,728 | $32.62 | $219,433.72 | filing |
| 2026-07-01 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 500 | $33.27 | $16,633.90 | filing |
| 2026-06-16 | Allan Jonathan· GENERAL COUNSEL & CORP SEC | Sale | 1,457 | $29.95 | $43,637.15 | filing |
| 2026-06-01 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 1,795 | $30.58 | $54,891.10 | filing |
| 2026-05-01 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 2,243 | $32.79 | $73,547.97 | filing |
| 2026-04-01 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 1,838 | $32.66 | $60,029.08 | filing |
| 2026-03-20 | Allan Jonathan· GENERAL COUNSEL & CORP SEC | Sale | 8,692 | $33.64 | $292,358.90 | filing |
| 2026-03-20 | Allan Jonathan· GENERAL COUNSEL & CORP SEC | Sale | 601 | $34.41 | $20,679.15 | filing |
| 2026-03-19 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 1,461 | $29.99 | $43,815.39 | filing |
| 2026-03-19 | Ticho Barry· CHIEF MEDICAL OFFICER | Option exercise | 1,365 | $2.19 | $2,989.35 | filing |
| 2026-03-18 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 6,100 | $31.28 | $190,831.18 | filing |
| 2026-03-18 | Allan Jonathan· GENERAL COUNSEL & CORP SEC | Sale | 4,222 | $31.28 | $132,080.20 | filing |
| 2026-03-18 | Leggett Thomas· Chief Financial Officer | Sale | 2,173 | $31.28 | $67,979.70 | filing |
| 2026-03-18 | Hoitt Jason· Chief Patient Officer | Sale | 1,762 | $31.28 | $55,122.06 | filing |
| 2026-03-18 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 483 | $31.79 | $15,353.99 | filing |
| 2026-03-18 | Allan Jonathan· GENERAL COUNSEL & CORP SEC | Sale | 334 | $31.79 | $10,617.46 | filing |
| 2026-03-18 | Leggett Thomas· Chief Financial Officer | Sale | 172 | $31.79 | $5,467.67 | filing |
| 2026-03-18 | Hoitt Jason· Chief Patient Officer | Sale | 139 | $31.79 | $4,418.64 | filing |
| 2026-03-18 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 103 | $32.85 | $3,383.55 | filing |
| 2026-03-18 | Allan Jonathan· GENERAL COUNSEL & CORP SEC | Sale | 72 | $32.85 | $2,365.20 | filing |
| 2026-03-18 | Leggett Thomas· Chief Financial Officer | Sale | 37 | $32.85 | $1,215.45 | filing |
| 2026-03-18 | Hoitt Jason· Chief Patient Officer | Sale | 30 | $32.85 | $985.50 | filing |
| 2026-03-17 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 3,577 | $32.74 | $117,108.83 | filing |
| 2026-03-17 | Ticho Barry· CHIEF MEDICAL OFFICER | Sale | 2,587 | $33.38 | $86,342.16 | filing |
| 2026-03-17 | Allan Jonathan· GENERAL COUNSEL & CORP SEC | Sale | 2,476 | $32.74 | $81,062.75 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.